To summarize the evidence characterizing the interactions between adrenal-regulating and calciumregulating hormones, and the relevance of these interactions to human cardiovascular and skeletal health.
INTRODUCTION
Beyond its known roles in the control of blood pressure and intravascular volume, the reninangiotensin-aldosterone system (RAAS) has been implicated as a major factor in the pathogenesis of cardiovascular disease [1, 2] , and clinical use of medications targeting the RAAS has a proven benefit for cardiovascular morbidity and mortality [3] [4] [5] [6] . New evidence suggests that inhibiting the RAAS may also play a role in improving skeletal health [7] . Conversely, components of the calcium-regulatory system, including parathyroid hormone (PTH), vitamin D metabolites, and the vitamin D receptor (VDR), have been increasingly implicated in the pathogenesis of cardiovascular disease [8 & ,9 & ,10] in addition to their known roles in bone mineral metabolism [11] [12] [13] . A growing body of evidence identifies bidirectional relationships between these adrenal-regulating and calcium-regulating systems that might underlie their shared associations with cardiovascular and bone health. A model summarizing the interactions described below is shown in Fig. 1 .
between the RAAS and the calcium-regulating hormone system. Early studies by Resnick and colleagues first described alterations in calcium metabolism and elevated PTH levels in patients with primary aldosteronism [26, 27] ; however, levels of vitamin D, a possible confounder, were not measured. More recently, Pilz et al. [14 && ] described 10 patients with primary aldosteronism with significantly higher PTH levels than 182 essential hypertensive controls despite similar 25 2 D], serum and urinary calcium measurements were equivalent to a group of 61 essential hypertensive controls. Increased PTH levels are so much a feature of aldosteronism that Rossi et al. [28 & ] demonstrated that elevated PTH levels could even serve as a helpful marker in distinguishing unilateral aldosterone-producing adenoma (APA) from bilateral adrenal hyperplasia as causes of primary aldosteronism in hypertensive patients, potentially because of an increased severity of hyperaldosteronism in APA. In each case, treatment of primary aldosteronism with either adrenalectomy or a mineralocorticoid receptor antagonist significantly reduced PTH to levels comparable with essential hypertensive controls [14 && ,15 && , 27,28 & ]. These studies identify a reversible state of hyperparathyroidism associated with autonomous aldosterone hypersecretion.
Given the evidence of elevated PTH in primary aldosteronism and animal studies describing bone loss in hyperaldosteronism [29, 30] ] evaluated PTH and calcium parameters in 116 patients with primary aldosteronism and 110 essential hypertensive controls, and assayed BMD and bone markers in a subset of 40 patients before and after medical or surgical treatment of primary aldosteronism. Again, patients with primary aldosteronism were found to have elevated PTH levels compared with controls. At 18-36 months after treatment of primary aldosteronism, Z-scores of BMD were improved at the lumbar spine, femoral neck, and total hip, and C-telopeptide, a marker of bone turnover, showed a nonsignificant trend toward improvement [32 & ]. In both studies, primary aldosteronism patients had similar 25(OH)D levels compared with their nonprimary aldosteronism controls. These studies have identified reversible loss of bone mass in primary aldosteronism and suggest a possible PTH-mediated mechanism of bone metabolism. However, additional mechanisms have been proposed, including a direct effect of aldosterone on bone, as mineralocorticoid receptor expression has been identified in osteoblasts and osteoclasts [33] . Studies are needed to explore in more depth the skeletal consequences of primary aldosterone excess.
In addition to primary aldosteronism, observational evidence supporting a relationship between aldosterone and skeletal outcomes has extended to other states of maladaptive RAAS activity, including congestive heart failure (CHF). In a case-control design involving 167 CHF patients with nontraumatic fracture and 668 age-matched and racematched controls, Carbone et al. [7] found an inverse association between the use of spironolactone, a mineralocorticoid receptor antagonist,
KEY POINTS
There is increasing evidence of bidirectional interactions between the RAAS and calcium-regulating hormones, with possible implications for cardiovascular and skeletal disease.
Primary aldosteronism is associated with reversible elevation in parathyroid hormone and reduction in bone mineral density.
Recent interventional evidence suggests that angiotensin II stimulates PTH acutely, whereas aldosterone may promote increased PTH chronically.
Primary hyperparathyroidism is associated with adverse cardiovascular risk, which may be mediated by the RAAS.
The 1,25(OH) 2 D-VDR complex can suppress the RAAS by inhibiting renin expression, and whether this interaction has cardiovascular consequences is under current study.
Future studies should evaluate these bidirectional interactions and their clinical consequences in more detail.
and fractures (OR 0.575; 95% CI 0.346-0.955). Although this was an uncontrolled, retrospective study in which levels of aldosterone, PTH, and other relevant calcium-related parameters were not available, the finding of an association between mineralocorticoid receptor blockade and reduced fracture rates supports the possibility of a clinically meaningful interplay between the RAAS and calcium-regulatory hormones. In addition, in a study of patients with advanced chronic kidney disease in which secondary hyperparathyroidism is common and these elevations in PTH are known to associate with adverse clinical outcomes [34] [35] [36] , Koiwa et al. [37 & ] found that clinical use of RAAS inhibitor medications was associated with lower PTH levels. Serum calcium levels did not differ with RAAS inhibitor medication use [37 & ], suggesting that blockade of the RAAS may have a direct effect on PTH levels in this population, though data on skeletal outcomes were not available.
Given the observational nature of these studies and the often limited availability of a complete assessment of calcium-regulatory parameters, the pathway by which aldosterone, or the RAAS, stimulates PTH is not clearly defined. However, investigators have hypothesized an indirect mechanism whereby chronic aldosterone excess induces hypercalciuria and hypocalcemia causing a reactive secondary hyperparathyroidism [38, 39] . Though not perfectly uniform between studies, various calcium Calcium-regulatory hormones Sodium-regulatory hormones (RAAS) [18] . (D) PTH augments the aldosterone response to AngII [19] , and PTH receptors are expressed in aldosteroneproducing cells [20] . (E) PTH directly stimulates renin in vitro [21] , and PTH infusion results in increased AngII levels [22] . (F) The 1,25(OH) 2 D-vitamin D receptor complex inhibits renin expression in vitro [23] , insufficient vitamin D status has been associated with increased plasma renin activity [24] , and vitamin D supplementation can downregulate the RAAS [25 && ]. 1,25(OH) 2 D, 1,25-dihydroxyvitamin D; Ca, calcium; ACE, angiotensin-converting enzyme; AGT, angiotensinogen; AngI, angiotensin I; AngII, angiotensin II; PTH, parathyroid hormone; RAAS, renin-angiotensin-aldosterone system. metrics were affected in the studies in primary aldosteronism described above, consistent with this proposed mechanism. Depending on the study, ionized calcium levels [27] ,27], implicating a possible aldosterone-induced calciuric effect. However, despite these changes in calcium, a more direct effect of aldosterone on PTH is also plausible, as mineralocorticoid receptor expression has been described in the parathyroid [16,17 && ]. Regardless of the mechanism, chronic exposure to aldosterone excess appears to drive higher levels of PTH and reduced BMD, at least in the observational studies of pathologic states of primary aldosteronism, CHF, and CKD (Fig. 1A) .
Cardiovascular and skeletal diseases
Primary aldosteronism, CHF, and CKD share common maladaptive RAAS activation, in particular aldosterone excess, with apparent effects on PTH and bone. However, the above observational studies in these conditions are limited in how definitively they can describe the regulation of PTH by the RAAS because of observational design and variable dietary conditions, medication use, and renal function. We recently reported the combined results of four small, controlled human interventional studies examining the control of PTH by the RAAS in relatively healthy individuals without primary aldosteronism, CHF, or CKD [17 && ]. Over 2 decades ago, Grant et al. [22] reported a dose-dependent increase in PTH because of infused angiotensin II in a controlled study of healthy volunteers. We extended this finding showing that an infusion of angiotensin II acutely raised circulating PTH and a short-acting oral angiotensin-converting enzyme (ACE) inhibitor (captopril) acutely lowered PTH to levels below baseline [17 && ]. Angiotensin II infusion raises both angiotensin II and aldosterone, and an ACE inhibitor similarly lowers both angiotensin II and aldosterone, meaning that changes in either angiotensin II or aldosterone might be suspected to drive the observed acute effect on PTH. To disaggregate the effects of each RAAS component, we showed that an infusion of aldosterone, which would presumably have a neutral or negative effect on angiotensin II levels, had no acute effect on circulating PTH [17 && ]. This finding, in contrast to the observational evidence from pathologic states of chronic hyperaldosteronism, supports the conclusion that acute stimulation of PTH by the RAAS is because of angiotensin II, and not aldosterone, and is further supported by the detection of angiotensin type 1 receptor (AT1R) expression in both normal and adenomatous parathyroid tissue [17 && ]. It appears that under physiologic conditions, angiotensin II acutely raises PTH levels, possibly via a direct action on the parathyroid (Fig. 1B) . Whether targeting angiotensin II can alter PTH in states of PTH excess remains to be shown and is the subject of the ongoing Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control (RAAS-PARC) Study (NCT01691781), an interventional study evaluating the effect of ACE inhibition on PTH levels in primary hyperparathyroidism (PHPT).
Though the acute interaction between angiotensin II and PTH represents a novel aspect of physiology, uncovering the impact of chronic RAAS activation or inhibition on PTH may have more meaningful clinical implications. Under randomized, placebo-controlled conditions, we demonstrated that 6 weeks of mineralocorticoid blockade with spironolactone (50 mg daily) resulted in a relative decrease in PTH compared with placebo [17 && ]. Though the effect was modest, it parallels what has been shown in primary aldosteronism, in which mineralocorticoid receptor antagonist use and surgical adrenalectomy resulted in lower PTH levels [14 && ,15 && ,27]. In this case, a mineralocorticoid-receptor-dependent effect on PTH was observed in relatively healthy individuals despite presumably normal aldosterone levels and minimal mineralocorticoid receptor activation at baseline. Together with the above observational evidence in primary aldosteronism, CHF, and CKD, this evidence from human interventions implicates aldosterone in the control of PTH under chronic conditions, and highlights mineralocorticoid receptor blockade as a potential means of targeting PTH and mineral metabolism that is worthy of further investigation. The ongoing study Effects of Eplerenone in Patients with Primary Hyperparathyroidism (EPATH) will evaluate the impact of eplerenone, a mineralocorticoid receptor antagonist, on circulating PTH levels, as well as skeletal and cardiovascular parameters in patients with PHPT [40 && ]. In sum, interventional studies demonstrate acute stimulation of PTH by angiotensin II that is not achieved with aldosterone alone. Chronically, increased aldosterone appears to induce hyperparathyroidism, possibly via direct effects on the parathyroid itself, or indirectly via induction of hypercalciuria. Treatment that inhibits aldosterone action correlates with lower PTH levels (or improved bone outcomes) in primary aldosteronism, CHF, CKD, and, to a lesser degree, in normal volunteers with a healthy RAAS. These interactions highlight a new paradigm of RAAS-mediated control of PTH, summarized in Fig. 1A and B .
CALCIUM-MEDIATED, PARATHYROID HORMONE-MEDIATED, AND VITAMIN-D-MEDIATED CONTROL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
In support of a bidirectional relationship between the RAAS and calcium-regulatory hormones, accruing evidence describes calcium ion-mediated, PTHmediated, and vitamin-D-mediated regulation of the RAAS (shown in Fig. 1C-F) .
PHPT has been linked to multiple cardiovascular outcomes, though some newer studies have had conflicting results [41] . PHPT has been associated with hypertension [42, 43] , coronary artery disease [44, 45] , left ventricular hypertrophy [46, 47] , and mortality [48] [49] [50] . Given the challenge of demonstrating a reversible effect on cardiovascular mortality, controlled interventional studies have assessed several intermediate cardiovascular phenotypes, including hypertension [51, 52] and arterial stiffness, and demonstrated improvement following parathyroidectomy [53, 54] . Aortic stiffness measured by pulse-wave velocity was increased in 44 patients with PHPT compared with 46 controls, despite adjustment for age and blood pressure [53] . In those treated with parathyroidectomy, pulsewave velocity (i.e. stiffness) and systolic blood pressure were reduced at 6-month follow-up [53] . Using another measure of vascular function that serves as a marker of cardiovascular risk, Rubin et al. [54] showed elevated arterial stiffness in 39 patients with mild PHPT, independent of typical cardiovascular risk factors. As with hypertension, arterial stiffness has been previously linked to maladaptive RAAS activity and can be improved with RAAS blockade [55, 56] , implicating the RAAS as one of several potential mediators of the adverse vascular phenotypes observed in PHPT. Other proposed mechanisms include indirect effects via hypertension and renal dysfunction, as well as direct effects of elevated PTH levels and the accompanying hypercalcemia [53, 57] .
Calcium has been associated with vascular calcification and atherosclerotic coronary artery disease [58] [59] [60] . Furthermore, calcium has been identified as a regulator of the RAAS at the level of renin [18] . As shown in Fig. 1C , calcium acutely inhibits juxtaglomerular cell release of renin via the calcium-sensing receptor (CaSR) [61] , whereas chronic hypercalcemia [62] and chronic stimulation of the CaSR [63] appear to increase plasma renin activity (PRA). These interactions highlight a key element of the complex crosstalk between the calcium-regulating and sodium-regulating systems and may contribute to the cardiovascular features of PHPT.
Over and above the effect on calcium, PTH itself has been implicated as a regulator of the RAAS. Even in populations without PHPT or hypercalcemia, PTH levels have been linked in both cross-sectional and prospective studies to multiple cardiovascular outcomes, including hypertension [64] , cardiovascular function [65 & ,66 & ], sudden cardiac death [67] , and cardiovascular and all-cause mortality [8 & ,68,69] . In support of an effect of PTH on the RAAS is evidence from both PHPT and healthy volunteers, based initially on a case report describing hyperaldosteronism in a patient with PHPT [70] . In this case, a patient presenting with hypercalcemia, hypertension, and hypokalemia was found to have both a parathyroid adenoma and primary aldosteronism, diagnosed by an elevated and nonsuppressible aldosterone level and suppressed renin activity, though no adrenal adenoma was identified. At 1 year after parathyroidectomy, both PHPT and primary aldosteronism had resolved, for the first time suggesting a direct connection between PTH and the adrenal axis. In an observational study of 134 patients with PHPT undergoing parathyroidectomy, Brunaud et al. [71] found that the preoperative PTH, but not calcium, level predicted the aldosterone level, with a stronger correlation found among those patients not taking antihypertensive medications, which might be expected to confound aldosterone levels. At 3 months' follow-up after parathyroidectomy, the correlation between PTH and aldosterone levels was lost [71] . The lack of a relationship in the postoperative setting could be because upon the resolution of pathologically high PTH levels, a relationship between PTH and aldosterone does not exist or is more difficult to detect under uncontrolled conditions given the numerous environmental inputs on the RAAS.
Several small interventional studies further support stimulation of the RAAS by PTH alone or with calcium, though a consensus has not yet been reached on the specific mechanism. In a controlled interventional study of five patients with PHPT, angiotensin II infusion resulted in an enhanced aldosterone response compared with matched controls [19] , and in a study of healthy volunteers, PTH infusion led to increased levels of urinary tetrahydroaldosterone [72] . These studies emphasize an action at the level of adrenocortical aldosterone synthesis, in which there is in-vitro evidence of PTH receptor expression [16, 20] and of a stimulatory effect of intracellular calcium [73] and PTH [74] on adrenal aldosterone-producing cells, providing a plausible direct effect of the calcium system on aldosterone (Fig. 1D ).
However, other interventional studies suggest a distinct relationship. Kovács et al. [75] studied 16 patients with PHPT, in whom basal aldosterone and PRA levels correlated positively with PTH levels. Following parathyroidectomy, aldosterone and PRA levels were reduced both at baseline and after stimulation with upright posture and furosemide to activate the RAAS [75] . In addition to such findings in patients with pathologic PTH excess, studies of healthy volunteers have also supported a more proximal action of PTH on the RAAS; PTH infusion in healthy adults resulted in an increase in angiotensin II [22] . These human studies corroborate in-vitro evidence of direct stimulation of renin by PTH [21, 76] (Fig. 1E) , an alternative or potentially complementary mechanism of PTH action on the RAAS. Thus, evidence from human studies supports multiple pleiotropic effects of PTH and calcium on the RAAS, with possible sites of action at renin, angiotensin II, and aldosterone.
It should be noted that studies have not been universally positive regarding stimulation of the RAAS by PTH. Bernini et al. [77] evaluated the RAAS in 20 patients with PHPT and found no difference in PRA, serum aldosterone, or urinary aldosterone compared with normotensive or hypertensive controls, or at 1 month and 6 months after parathyroidectomy. However, these negative findings may have been because of incomplete control of posture, interfering medications, and sodium intake, all of which can dramatically alter the measurements of the RAAS. Furthermore, the interventional studies described above are limited by the lack of a complete assessment of the calciumregulating apparatus, in particular levels of 25(OH)D and 1,25(OH) 2 D, which might allow more definitive conclusions to be drawn.
Like calcium and PTH, vitamin D has also been implicated in control of the RAAS, with potential clinical consequences. In observational analyses, vitamin D deficiency has been associated with hypertension and cardiovascular disease [78] , a relationship that may depend on the RAAS. In animal studies, the VDR bound to its ligand, 1,25(OH) 2 D, has been shown to negatively regulate renin [23, 79, 80] (Fig. 1F ). In humans, several crosssectional studies have also demonstrated an association between vitamin D metabolites and components of the RAAS: 25(OH)D levels have been shown to inversely correlate with PRA [24] as well as with elevated circulating levels of angiotensin II [81] , signifying increased RAAS activation in states of low 25(OH)D. In a large cohort of 3296 patients presenting for coronary angiogram, both 25(OH)D and 1,25(OH) 2 D were independently associated with renin and angiotensin II concentrations [82] . Further, a functional polymorphism in the VDR, when combined with 25(OH)D levels, predicted PRA in hypertensive and normotensive individuals [83] . This cross-sectional evidence suggests a role for the vitamin D-VDR complex in negatively regulating the RAAS, which may underlie epidemiologic associations between 25(OH)D deficiency and cardiovascular disease.
In interventional studies, sensitivity to angiotensin II infusion, manifested by adrenal aldosterone production and vascular responses to angiotensin II, has been negatively correlated with activity of the local tissue RAAS [84, 85] . Lower 25(OH)D levels have been associated with blunted sensitivity to angiotensin II [81] , a state of local RAAS excess implicated in adverse vascular outcomes [84, 86, 87] . Furthermore, we have previously shown that high-dose vitamin D 3 supplementation can reduce local tissue-RAAS overactivity, restoring sensitivity to angiotensin II in obese hypertensive adults with 25(OH)D deficiency [25 && ]. The ongoing Evaluating Hormonal Mechanisms for Vitamin D Receptor Agonist Therapy in Diabetes (VALIDATE-D) Study is a randomized, placebo-controlled study that seeks to evaluate the ability of the direct VDR ligand, 1,25(OH) 2 D, to downregulate circulating and local RAAS activity and possibly improve vascular health in diabetes [88] . A demonstration of downregulation of the RAAS by 1,25(OH) 2 D could provide additional evidence of a clinically relevant and complex interplay between calcium-regulating hormones and the RAAS.
CONCLUSION
Excess RAAS activity, excess PTH and calcium, and insufficient vitamin D status have all been associated with adverse clinical outcomes, both cardiovascular and skeletal. Recent observational and interventional studies in both pathologic states and normal physiology describe the existence of meaningful bidirectional crosstalk between the RAAS and calcium-regulating hormone systems. Additional investigation is needed to further clarify the extent of these complex endocrine interactions and evaluate the clinical impacts of targeting these systems on cardiovascular and bone health.
